AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 11:49:04 16/07/2024 pm IST 5-day change 1st Jan Change
7.57 USD +27.66% Intraday chart for AngioDynamics, Inc. +32.83% -4.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Gain in Afternoon Trading MT
AngioDynamics Shares Rise After Fiscal Q4 Results, Share Repurchase Program MT
Transcript : AngioDynamics, Inc., Q4 2024 Earnings Call, Jul 16, 2024
AngioDynamics, Inc. announces an Equity Buyback for $15 million worth of its shares. CI
AngioDynamics, Inc. Reports Earnings Results for the Fourth Quarter Ended May 31, 2024 CI
AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2025 CI
Earnings Flash (ANGO) ANGIODYNAMICS Posts Q4 Revenue $71.1M, vs. Street Est of $70.9M MT
Earnings Flash (ANGO) ANGIODYNAMICS Reports Q4 Loss $-0.05, vs. Street Est of $-0.17 MT
AngioDynamics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended May 31, 2024 CI
AngioDynamics, Inc. authorizes a Buyback Plan. CI
AngioDynamics, Inc.(NasdaqGS:ANGO) dropped from Russell 2000 Defensive Index CI
AngioDynamics, Inc.(NasdaqGS:ANGO) dropped from Russell 2000 Value-Defensive Index CI
AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System MT
AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV) CI
North American Morning Briefing : Inflation Data, -2- DJ
Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target MT
AngioDynamics Shares Jump After Fiscal Q3 Results, FDA Clearance For Device MT
AngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 System DJ
Transcript : AngioDynamics, Inc., Q3 2024 Earnings Call, Apr 04, 2024
AngioDynamics Gets FDA Clearance For Pulmonary Embolism Treatment DJ
Earnings Flash (ANGO) ANGIODYNAMICS Reports Q3 Revenue $66M MT
AngioDynamics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 CI
AngioDynamics, Inc. Reports Consolidated Goodwill Impairment for Third Quarter Ended February 29, 2024 CI
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024 CI
AngioDynamics, Inc. Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE CI
Chart AngioDynamics, Inc.
More charts
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.93 USD
Average target price
14.67 USD
Spread / Average Target
+147.33%
Consensus
  1. Stock Market
  2. Equities
  3. ANGO Stock
  4. News AngioDynamics, Inc.
  5. AngioDynamics Shares Rise After Fiscal Q4 Results, Share Repurchase Program